Refining clinical features and therapeutic options of new daily persistent headache: a retrospective study of 63 patients in India
Refining clinical features and therapeutic options of new daily persistent headache: a retrospective study of 63 patients in India
复制标题
DOI：
10.1007/s10194-012-0461-6
复制
发表时间：
2012-08-01
影响因子：
7.4
通讯作者：
Mahato, Pinaki
中科院分区：
文献类型：
--
作者：
Prakash, Sanjay;Saini, Samir;Mahato, Pinaki
本回顾性研究的目的是提供NDPH患者的临床特征和治疗结果的数据（符合Kung等人的标准）。在2007-2012年的5年期间共观察了63例患者。超过三分之一（35%）的患者有偏头痛特征；65%的患者符合ICHD-II标准。两组在大多数临床和流行病学特征上相似。然而，偏头痛特征在有发作性偏头痛病史的患者中更为常见（尽管统计上不显着）。中位随访9个月后，37%的患者表现出“极好的”反应（每月没有或少于1次头痛）。另外30%的患者有“良好”反应（每月头痛频率或天数减少50%）。在持续时间小于6个月的患者中，良好的反应更多（统计学上无统计学意义）。已知诱因的患者预后较好。接受泼尼松龙甲酯和丙戊酸钠静脉治疗的患者疗效更好。我们建议前瞻性和对照研究来证实我们的观察结果。
The aim of this retrospective study was to provide data on the clinical features and treatment outcomes of patients with NDPH (fulfilling Kung et al.'s criteria). A total of 63 patients were observed during a 5-yr period (2007-2012). More than one-third (35 %) patients had migrainous features; 65 % patients fulfilled the ICHD-II criteria. Both groups were similar in most clinical and epidemiological features. However, migrainous features were more common in patients with a prior history of episodic migraine (though statistically not significant). After a median follow-up of 9 months, 37 % patients showed "excellent" response (no or less than 1 headache per month). Another 30 % patients had "good" response (> 50 % reduction in headache frequency or days per month). Excellent response was more in patients with a history of less than 6 months duration (statistically not significant). Patients with a recognized trigger showed better prognosis. Response was better in patients who received intravenous therapy of methyl prednisolone and sodium valproate. We suggest prospective and controlled studies to confirm our observations.